Chiusura precedente | 2,6400 |
Aperto | 2,6500 |
Denaro | 2,4400 x 100 |
Domanda | 2,5900 x 100 |
Min-Max giorno | 2,3500 - 2,6500 |
Intervallo di 52 settimane | 2,3500 - 8,3500 |
Volume | |
Media Volume | 81.061 |
Capitalizzazione | 19,626M |
Beta (mensile su 5 anni) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,8800 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Discoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable
BullFrog AI’s Patented Drug BF-223 Demonstrates Anti-Cancer Activity Against Glioblastoma in Established Animal ModelGAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the an
GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the Company’s recent partnerships, revenue and growth strategy, and portfoli